IMMUNEERING

Immuneering is advancing a robust pipeline of novel drug programs starting with IMM-1-104, which is designed to achieve pan-KRAS/NRAS activity through deep, cyclic inhibition of MEK. This differentiated approach aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, basal level of signaling designed to spare healthy cells... Immuneering's lead product candidate IMM-1-104 aims to achieve pan-KRAS/NRAS activity while sparing normal healthy cells by driving deep cyclic inhibition of the MAPK pathway. Our earlier stage programs include six novel drug programs for patients with solid tumors and two that seek to bring precision medicine to patients with Alzheimer's disease... Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data in new and..

Also known as: Immuneering Corporation